Tirzepatide vs MOTS-c

A dual GIP and GLP-1 receptor agonist producing the largest sustained weight reductions of any drug currently licensed, averaging 20–22% body weight loss in clinical trials.

A 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA gene, with research interest in metabolic regulation, insulin sensitivity, and exercise capacity.

Tirzepatide activates both GIP and GLP-1 receptors, a combination that appears to amplify glucose-dependent insulin secretion, slow gastric emptying, and suppress appetite beyond what either pathway achieves alone.

MOTS-c moves between mitochondria, cytosol, and nucleus depending on metabolic state. It activates AMPK, improves glucose uptake, and regulates nuclear gene expression related to metabolic homeostasis. Circulating MOTS-c declines with age.

2.5 mg weekly, titrated up to 15 mg weekly

5–10 mg, 1–3 times per week (research protocols)

~5 days

~3 hours

Subcutaneous once weekly

Subcutaneous

approved

investigational

Not yet listed

£30 · £3.0/mg via Peptides UK